These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20040334)

  • 1. Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.
    Kuhn UD; Anschütz M; Schmücker K; Schug BS; Hippius M; Blume HH
    Int J Clin Pharmacol Ther; 2010 Jan; 48(1):1-10. PubMed ID: 20040334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.
    Kumagai S; Komada F; Kita T; Morinobu A; Ozaki S; Ishida H; Sano H; Matsubara T; Okumura K
    Pharm Res; 2004 Feb; 21(2):324-9. PubMed ID: 15032315
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Mthiyane T; Millard J; Adamson J; Balakrishna Y; Connolly C; Owen A; Rustomjee R; Dheda K; McIlleron H; Pym AS
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
    Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
    Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects.
    Brocvielle H; Muret P; Goydadin AC; Boone P; Broly F; Kantelip JP; Humbert P
    Skin Pharmacol Appl Skin Physiol; 2003; 16(6):386-92. PubMed ID: 14528063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine.
    Hou ZD; Xiao ZY; Gong Y; Zhang YP; Zeng QY
    BMC Pharmacol Toxicol; 2014 Nov; 15():64. PubMed ID: 25413361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events.
    Tanigawara Y; Kita T; Aoyama N; Gobara M; Komada F; Sakai T; Kasuga M; Hatanaka H; Sakaeda T; Okumura K
    Biol Pharm Bull; 2002 Aug; 25(8):1058-62. PubMed ID: 12186410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects.
    Kita T; Sakaeda T; Adachi S; Sakai T; Aoyama N; Hatanaka H; Kasuga M; Okumura K
    Biol Pharm Bull; 2001 Oct; 24(10):1176-80. PubMed ID: 11642327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population.
    Ma JJ; Liu CG; Li JH; Cao XM; Sun SL; Yao X
    Clin Chim Acta; 2009 Sep; 407(1-2):30-5. PubMed ID: 19560446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.
    Chen M; Xia B; Chen B; Guo Q; Li J; Ye M; Hu Z
    Can J Gastroenterol; 2007 Mar; 21(3):155-8. PubMed ID: 17377643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians.
    Kotila OA; Fawole OI; Olopade OI; Ayede AI; Falusi AG; Babalola CP
    Pharmacogenet Genomics; 2019 Jul; 29(5):106-113. PubMed ID: 30882558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.
    Ricart E; Taylor WR; Loftus EV; O'Kane D; Weinshilboum RM; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
    Am J Gastroenterol; 2002 Jul; 97(7):1763-8. PubMed ID: 12135032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Acetyltransferase 2 (NAT2) polymorphism as a risk modifier of susceptibility to pediatric acute lymphoblastic leukemia.
    Kamel AM; Ebid GT; Moussa HS
    Tumour Biol; 2015 Aug; 36(8):6341-8. PubMed ID: 25804798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine.
    Yokogawa K; Nakaharu T; Ishizaki J; Ozaki E; Takeda Y; Mabuchi H; Matsushita R; Kimura K; Nakashima E; Ichimura F; Miyamoto K
    Int J Pharm; 2001 Oct; 229(1-2):183-91. PubMed ID: 11604271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.
    Adkison KK; Vaidya SS; Lee DY; Koo SH; Li L; Mehta AA; Gross AS; Polli JW; Humphreys JE; Lou Y; Lee EJ
    J Pharm Sci; 2010 Feb; 99(2):1046-62. PubMed ID: 19569219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
    Taggart AJ; McDermott BJ; Roberts SD
    Clin Pharmacokinet; 1992 Oct; 23(4):311-20. PubMed ID: 1356683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis.
    Yee J; Kim SM; Han JM; Lee N; Yoon HY; Gwak HS
    Sci Rep; 2020 Feb; 10(1):3658. PubMed ID: 32107440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus.
    Sabbagh N; Delaporte E; Marez D; Lo-Guidice JM; Piette F; Broly F
    Pharmacogenetics; 1997 Apr; 7(2):131-5. PubMed ID: 9170150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.
    Hein DW; Millner LM
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):9-21. PubMed ID: 33094670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.
    Kubota R; Ohno M; Hasunuma T; Iijima H; Azuma J
    Eur J Clin Pharmacol; 2007 Oct; 63(10):927-33. PubMed ID: 17665185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.